EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma

Yujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, Takuji Hayashi, Yu Ishizuya, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Nesrine Sassi, Takeshi Ujike, Tetsuya Takao, Shun Umeda und 12 weitere

Cancer Treatment and Research Communications · 2026 · 48 · 101255

DOI: 10.1016/j.ctarc.2026.101255 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yujiro Hayashi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka International Cancer Institute, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Enfortumab vedotin (EV) is widely used for metastatic urothelial carcinoma, either as monotherapy or in combination with pembrolizumab (EV + P). However, these regimens differ in patient characteristics, treatment lines, and intensity. Direct comparisons of adverse event profiles, particularly early toxicities and their risk factors, remain limited. METHODS: We conducted a multicenter retrospective cohort study including patients treated with EV monotherapy (n = 165) or EV + P (n = 76) at Osaka University Hospital and affiliated institutions between November 2021 and August 2025. A total of 221 patients with complete clinical and laboratory data were analyzed. The incidence and time-to-onset of adverse events were compared between regimens. Logistic regression and time-to-event analyses were performed to identify factors associated with skin toxicity. RESULTS: The incidence and time-to-onset of adverse events were comparable between EV and EV + P. Skin toxicity was the most frequent and early-onset adverse event in both groups. Multivariable analysis identified baseline performance status and neutrophil-to-lymphocyte ratio (NLR) as independent predictors of skin toxicity, whereas treatment regimen was not associated with risk. Patients with high NLR (≥6) and poor performance status showed a lower incidence of skin toxicity, whereas those with low NLR (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellLymphocytesNeutrophilsUrologic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

Adverse eventEnfortumab vedotinNeutrophil-to-lymphocyte ratioSkin toxicityUrothelial carcinoma

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Osaka International Cancer Institute, Japan.
  • Department of Urology, Graduate School of Medicine, The University of Osaka, Japan. Electronic address: kawashima@uro.med.osaka-u.ac.jp.
  • Department of Urology, Graduate School of Medicine, The University of Osaka, Japan.
  • Department of Urology, Osaka Rosai Hospital, Japan.
  • Department of Urology, Osaka General Medical Center, Japan.
  • Department of Urology, Toyonaka Municipal Hospital, Japan.

Zitieren

APA

Hayashi, Y., Kawashima, A., Yamamoto, Y., Hayashi, T., Ishizuya, Y., Horitani, H., Inoguchi, S., Horibe, Y., Sassi, N., Ujike, T., Takao, T., Umeda, S., Takayama, H., Yazawa, K., Tsutsui, K., Yamazaki, H., Inoue, H., Asakura, T., Kobayashi, M., …, & Nonomura, N. (2026). Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma. Cancer Treatment and Research Communications, 48, 101255. https://doi.org/10.1016/j.ctarc.2026.101255

Vancouver

Hayashi Y, Kawashima A, Yamamoto Y, Hayashi T, Ishizuya Y, Horitani H, et al. Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma. Cancer Treatment and Research Communications. 2026;48:101255. doi:10.1016/j.ctarc.2026.101255

BibTeX
@article{Hayashi2026,
  author = {Hayashi, Yujiro and Kawashima, Atsunari and Yamamoto, Yoshiyuki and Hayashi, Takuji and Ishizuya, Yu and Horitani, Hiromu and Inoguchi, Shunsuke and Horibe, Yuki and Sassi, Nesrine and Ujike, Takeshi and Takao, Tetsuya and Umeda, Shun and Takayama, Hitoshi and Yazawa, Koji and Tsutsui, Kenji and Yamazaki, Hajime and Inoue, Hitoshi and Asakura, Toshihisa and Kobayashi, Masao and Okada, Koichi and Nakayama, Masashi and Kato, Taigo and Hatano, Koji and Nonomura, Norio},
  title = {Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {48},
  pages = {101255},
  doi = {10.1016/j.ctarc.2026.101255}
}
Kostenlos starten →